Bearish for Pharma: Pregabalin Moves to Schedule H1; Cipla, DRL Sales

The Union health ministry has reclassified Pregabalin, a nerve pain medication, to Schedule H1. This regulatory change mandates stricter controls, requiring a prescription for purchase and obliging pharmacies to maintain detailed records and display prominent warnings, aiming to curb its widespread misuse.

This move is significant for the Indian pharmaceutical sector as it directly impacts the sales and distribution of a commonly used drug. While intended to address public health concerns regarding drug misuse, it will inevitably lead to increased compliance burdens and potentially reduced sales volumes for manufacturers and distributors.

Pharmaceutical companies that manufacture or have a substantial market share in Pregabalin, such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, could experience a negative impact. This includes higher operational costs due to stricter record-keeping and potential decline in over-the-counter sales, affecting their domestic revenue streams.

Traders should monitor the quarterly results of pharmaceutical companies for any commentary on the impact of this regulatory change on their Pregabalin sales. Also, observe any further regulatory actions on other commonly misused drugs, as this could signal a broader trend in drug control.

• •Pregabalin moved to Schedule H1 by Union health ministry.
• •Aims to curb misuse, especially among youth.
• •Now requires strict prescriptions.
• •Pharmacies must maintain records and display prominent warnings.
• •Risk flag: Reduced sales volume